Beta-thalassemia pathophysiology: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Beta-thalassemia}} {{CMG}} ==Overview== ==Pathophysiology== ===Genetics=== The genetic mutations present in β thalassemias are very diverse, and a number of dif...")
 
No edit summary
Line 11: Line 11:
* '''Nondeletion forms''': These defects generally involve a single base substitution or small deletion or inserts near or upstream of the β globin gene. Most commonly, mutations occur in the promoter regions preceding the beta-globin genes. Less often, abnormal splice variants are believed to contribute to the disease.
* '''Nondeletion forms''': These defects generally involve a single base substitution or small deletion or inserts near or upstream of the β globin gene. Most commonly, mutations occur in the promoter regions preceding the beta-globin genes. Less often, abnormal splice variants are believed to contribute to the disease.
* '''Deletion forms''': Deletions of different sizes involving the β globin gene produce different syndromes such as (β<sup>o</sup>) or hereditary persistence of fetal hemoglobin syndromes.
* '''Deletion forms''': Deletions of different sizes involving the β globin gene produce different syndromes such as (β<sup>o</sup>) or hereditary persistence of fetal hemoglobin syndromes.
The severity of the disease depends on the nature of the mutation.
* Mutations are characterized as (β<sup>o</sup>) if they prevent any formation of β chains.
* Mutations are characterized as (β<sup>+</sup>) if they allow some β chain formation to occur.
* Alleles without a mutation that reduces function is characterized as (β). (Note that the "+" in β<sup>+</sup> is relative to β<sup>o</sup>, not β.)
In either case there is a relative excess of α chains, but these do not form tetramers: rather, they bind to the [[red blood cell]] membranes, producing membrane damage, and at high concentrations they form toxic aggregates.
   
   
==References==
==References==

Revision as of 16:27, 21 September 2012

Beta-thalassemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Beta-thalassemia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Beta-thalassemia pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Beta-thalassemia pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Beta-thalassemia pathophysiology

CDC on Beta-thalassemia pathophysiology

Beta-thalassemia pathophysiology in the news

Blogs on Beta-thalassemia pathophysiology

Directions to Hospitals Treating Beta-thalassemia

Risk calculators and risk factors for Beta-thalassemia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pathophysiology

Genetics

The genetic mutations present in β thalassemias are very diverse, and a number of different mutations can cause reduced or absent β globin synthesis. Two major groups of mutations can be distinguished:

  • Nondeletion forms: These defects generally involve a single base substitution or small deletion or inserts near or upstream of the β globin gene. Most commonly, mutations occur in the promoter regions preceding the beta-globin genes. Less often, abnormal splice variants are believed to contribute to the disease.
  • Deletion forms: Deletions of different sizes involving the β globin gene produce different syndromes such as (βo) or hereditary persistence of fetal hemoglobin syndromes.

The severity of the disease depends on the nature of the mutation.

  • Mutations are characterized as (βo) if they prevent any formation of β chains.
  • Mutations are characterized as (β+) if they allow some β chain formation to occur.
  • Alleles without a mutation that reduces function is characterized as (β). (Note that the "+" in β+ is relative to βo, not β.)

In either case there is a relative excess of α chains, but these do not form tetramers: rather, they bind to the red blood cell membranes, producing membrane damage, and at high concentrations they form toxic aggregates.


References


Template:WikiDoc Sources